Phase I clinical study of peptide vaccine using novel tumor-associated antigen TTK against advanced esophageal carcinoma
Phase 1
- Conditions
- Advanced esophageal cancer refractory to standard therapeutic modality
- Registration Number
- JPRN-UMIN000001014
- Lead Sponsor
- niversity of Tokyo
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 6
Inclusion Criteria
Not provided
Exclusion Criteria
Pregnancy Uncontrolled infection Uncontrolled brain metastasis
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety
- Secondary Outcome Measures
Name Time Method Antitumor immune responses
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What is the mechanism of action of TTK peptide vaccine in advanced esophageal cancer?
How does TTK peptide vaccine compare to standard-of-care treatments for advanced esophageal cancer?
What biomarkers are associated with response to TTK peptide vaccine in esophageal cancer patients?
What are the known adverse events of TTK peptide vaccine therapy in clinical trials?
Are there combination therapies involving TTK peptide vaccine for advanced esophageal cancer?